Redx Pharma plc. (3/30/17). "Press Release: Redx Pharma Awarded US$1 Million Grant by CARB-X".

	Organisation	Redx Pharma plc (AIM: REDX)
	Group	Redx Pharma (Group)
	Organisation 2	CARB-X (Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator)
	Product	antibiotic
	Product 2	drug development
	Index term	Redx Pharma–CARB-X: grant, 201703– grant $1m over 18 months to advance candidates for drug resistant Gram-negative bacteria
	Person	Murray, Neil (Redx Pharma 201112 CEO)

> Redx selected as one of 11 initial candidates after competitive global selection process in recognition of innovative science programs

> Collaborative grant in anti-infectives enables Redx to advance its Gram-negative program with a prospective partner

Redx Pharma is pleased to announce that it has been awarded a US$1 million grant by CARB-X, one of the world’s largest public-private partnerships, launched in July 2016 to accelerate global antibacterial innovation and research. The 11 successful projects were selected through a competitive process from 168 applications from around the world. The awarded grants were based on the merits of each of the company’s research proposals, as evaluated by the CARB-X Advisory Board and the CARB-X team.

Today’s announcement by CARB-X showcases the first projects selected for the Powered by CARB-X portfolio, spotlighting Redx as a highly-respected partner of choice on a global stage. Redx will receive US$1 million over 18 months, with an option for future tiered milestone payments, to drive scientific progress against globally challenging drug resistant Gram-negative bacteria. This collaboration with CARB-X enables Redx to move its Gram-negative program into the next stage of development with a prospective partner.

Dr Neil Murray, Chief Executive Officer of Redx Pharma, said: "We are delighted to be collaborating with CARB-X, a truly innovative initiative that is targeting the development of new life-saving antibacterials and diagnostics. Receiving this grant today is testament to the great science that exists at Redx. This grant cements a path forward for our recently announced strategy, to secure external partners to ensure that our high quality anti-infective science will continue whilst we sharpen our focus on the clinical development of our oncology and immunology programs."

Record changed: 2023-06-05